The DOI matches its Crossref record; 117 of the 117 references it cites were found in a registry or an index.
The biology of ovarian cancer: new opportunities for translation
Open accessAbstract
Over the past two decades, the 5-year survival for ovarian cancer patients has substantially improved owing to more effective surgery and treatment with empirically optimized combinations of cytotoxic drugs, but the overall cure rate remains approximately 30%. Many investigators think that further empirical trials using combinations of conventional agents are likely to produce only modest incremental improvements in outcome. Given the heterogeneity of this disease, increases in long-term survival might be achieved by translating recent insights at the molecular and cellular levels to personalize individual strategies for treatment and to optimize early detection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nuclear factor-κB in cancer development and progression
Karin, M. (2006) · Nature · doi:10.1038/nature04870 · Cited by 3,519
Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M. N., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020177 · Cited by 3,397
Induction of autophagy and inhibition of tumorigenesis by beclin 1
Liang, X. H., Jackson, S., Seaman, M., Brown, K., Kempkes, B., Hibshoosh, H., & Levine, B. (1999) · Nature · doi:10.1038/45257 · Cited by 3,347
Rubin, M., & Stephen, C. D. (1993) · Cited by 3,149
Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer
Armstrong, D. K., Bundy, B., Wenzel, L., Huang, H. Q., Baergen, R., Lele, S., Copeland, L. J., Walker, J. L., & Burger, R. A. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052985 · Cited by 2,625
Sato, E., Olson, S. H., Ahn, J., Bundy, B., Nishikawa, H., Qian, F., Jungbluth, A. A., Frosina, D., Gnjatic, S., Ambrosone, C., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509182102 · Cited by 2,372
A Radioimmunoassay Using a Monoclonal Antibody to Monitor the Course of Epithelial Ovarian Cancer
Bast, R. C., Klug, T. L., John, E. S., Jenison, E., Niloff, J. M., Lazarus, H., Berkowitz, R. S., Leavitt, T., Griffiths, C. T., Parker, L., et al. (1983) · New England Journal of Medicine · doi:10.1056/nejm198310133091503 · Cited by 2,135
Self-citationSaam, J., Arnell, C., Theisen, A., Moyes, K., Marino, I., Roundy, K. M., & Wenstrup, R. J. (2015) · Oncology · doi:10.1159/000437307 · Cited by 1,526
Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome
Tothill, R. W., Tinker, A. V., George, J., Brown, R., Fox, S. B., Lade, S., Johnson, D. S., Trivett, M. K., Etemadmoghadam, D., Locandro, B., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0196 · Cited by 1,467
Identification and Characterization of Ovarian Cancer-Initiating Cells from Primary Human Tumors
Zhang, S., Balch, C., Chan, M. W., Lai, H.-C., Matei, D., Schilder, J. M., Yan, P. S., Huang, T. H.-M., & Nephew, K. P. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0364 · Cited by 1,293
Cited by
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,925
VarScan 2: Somatic mutation and copy number alteration discovery in cancer by exome sequencing
Koboldt, D. C., Zhang, Q., Larson, D. E., Shen, D., McLellan, M. D., Lin, L., Miller, C. A., Mardis, E. R., Ding, L., & Wilson, R. K. (2012) · Genome Research · doi:10.1101/gr.129684.111 · Cited by 4,905
Di Leva, G., Garofalo, M., & Croce, C. M. (2014) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012513-104715 · Cited by 1,672
Repair Pathway Choices and Consequences at the Double-Strand Break
Ceccaldi, R., Rondinelli, B., & D’Andrea, A. D. (2016) · Trends in Cell Biology · doi:10.1016/j.tcb.2015.07.009 · Cited by 1,499
Mucins in cancer: function, prognosis and therapy
Kufe, D. W. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2761 · Cited by 1,396
Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer
Konstantinopoulos, P. A., Ceccaldi, R., Shapiro, G. I., & D'Andrea, A. D. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0714 · Cited by 945
Homologous-recombination-deficient tumours are dependent on Polθ-mediated repair
Ceccaldi, R., Liu, J. C., Amunugama, R., Hajdu, I., Primack, B., Petalcorin, M. I. R., O’Connor, K. W., Konstantinopoulos, P. A., Elledge, S. J., Boulton, S. J., et al. (2015) · Nature · doi:10.1038/nature14184 · Cited by 903
High-Grade Serous Ovarian Cancer: Basic Sciences, Clinical and Therapeutic Standpoints
Lisio, M.-A., Fu, L., Goyeneche, A., Gao, Z.-H., & Telleria, C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20040952 · Cited by 680
Prognostically relevant gene signatures of high-grade serous ovarian carcinoma
Verhaak, R. G. W., Tamayo, P., Yang, J.-Y., Hubbard, D., Zhang, H., Creighton, C. J., Fereday, S., Lawrence, M., Carter, S. L., Mermel, C. H., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci65833 · Cited by 569
Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research
Kipps, E., Tan, D. S. P., & Kaye, S. B. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3432 · Cited by 562
Ultrasensitive detection of circulating exosomes with a 3D-nanopatterned microfluidic chip
Zhang, P., Zhou, X., He, M., Shang, Y., Tetlow, A. L., Godwin, A. K., & Zeng, Y. (2019) · Nature Biomedical Engineering · doi:10.1038/s41551-019-0356-9 · Cited by 554
In situ-forming injectable hydrogels for regenerative medicine
Yang, J.-A., Yeom, J., Hwang, B. W., Hoffman, A. S., & Hahn, S. K. (2014) · Progress in Polymer Science · doi:10.1016/j.progpolymsci.2014.07.006 · Cited by 532
Gillet, J.-P., Calcagno, A. M., Varma, S., Marino, M., Green, L. J., Vora, M. I., Patel, C., Orina, J. N., Eliseeva, T. A., Singal, V., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1111840108 · Cited by 477
Iron addiction: a novel therapeutic target in ovarian cancer
Basuli, D., Tesfay, L., Deng, Z., Paul, B., Yamamoto, Y., Ning, G., Xian, W., McKeon, F., Lynch, M., Crum, C. P., et al. (2017) · Oncogene · doi:10.1038/onc.2017.11 · Cited by 465
The Wnt/β-catenin pathway in ovarian cancer: A review
Arend, R. C., Londoño-Joshi, A. I., Straughn, J. M., & Buchsbaum, D. J. (2013) · Gynecologic Oncology · doi:10.1016/j.ygyno.2013.09.034 · Cited by 458
A novel defined pyroptosis-related gene signature for predicting the prognosis of ovarian cancer
Ye, Y., Dai, Q., & Qi, H. (2021) · Cell Death Discovery · doi:10.1038/s41420-021-00451-x · Cited by 451
Ovarian cancer: Current status and strategies for improving therapeutic outcomes
Chandra, A., Pius, C., Nabeel, M., Nair, M., Vishwanatha, J. K., Ahmad, S., & Basha, R. (2019) · Cancer Medicine · doi:10.1002/cam4.2560 · Cited by 449
The genesis and evolution of high-grade serous ovarian cancer
Bowtell, D. D. L. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2946 · Cited by 445
Cheung, H. W., Cowley, G. S., Weir, B. A., Boehm, J. S., Rusin, S., Scott, J. A., East, A., Ali, L. D., Lizotte, P. H., Wong, T. C., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1109363108 · Cited by 423
The causes and consequences of polyploidy in normal development and cancer
Davoli, T., & de Lange, T. (2011) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-092910-154234 · Cited by 424
High-grade serous ovarian cancer arises from fallopian tube in a mouse model
Kim, J., Coffey, D. M., Creighton, C. J., Yu, Z., Hawkins, S. M., & Matzuk, M. M. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1117135109 · Cited by 398
Jokerst, J. V., Cole, A. J., Van de Sompel, D., & Gambhir, S. S. (2012) · ACS Nano · doi:10.1021/nn304347g · Cited by 397
Yang, D., Sun, Y., Hu, L., Zheng, H., Ji, P., Pecot, C. V., Zhao, Y., Reynolds, S., Cheng, H., Rupaimoole, R., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2012.12.020 · Cited by 394
Discovery of multi-dimensional modules by integrative analysis of cancer genomic data
Zhang, S., Liu, C.-C., Li, W., Shen, H., Laird, P. W., & Zhou, X. J. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks725 · Cited by 374
Yeung, T.-L., Leung, C. S., Yip, K.-P., Au Yeung, C. L., Wong, S. T. C., & Mok, S. C. (2015) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00188.2015 · Cited by 377
Cheon, D.-J., Tong, Y., Sim, M.-S., Dering, J., Berel, D., Cui, X., Lester, J., Beach, J. A., Tighiouart, M., Walts, A. E., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1256 · Cited by 373
The role of photodynamic therapy in overcoming cancer drug resistance
Spring, B. Q., Rizvi, I., Xu, N., & Hasan, T. (2015) · Photochemical & Photobiological Sciences · doi:10.1039/c4pp00495g · Cited by 335
Yokoi, A., Yoshioka, Y., Yamamoto, Y., Ishikawa, M., Ikeda, S.-I., Kato, T., Kiyono, T., Takeshita, F., Kajiyama, H., Kikkawa, F., et al. (2017) · Nature Communications · doi:10.1038/ncomms14470 · Cited by 334
Tumor targeted quantum dot-mucin 1 aptamer-doxorubicin conjugate for imaging and treatment of cancer
Savla, R., Taratula, O., Garbuzenko, O., & Minko, T. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.02.015 · Cited by 314
Frequent Downregulation of miR-34 Family in Human Ovarian Cancers
Corney, D. C., Hwang, C.-I., Matoso, A., Vogt, M., Flesken-Nikitin, A., Godwin, A. K., Kamat, A. A., Sood, A. K., Ellenson, L. H., Hermeking, H., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2642 · Cited by 308
Risk and prognosis of ovarian cancer in women with endometriosis: a meta-analysis
Kim, H. S., Kim, T. H., Chung, H. H., & Song, Y. S. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.29 · Cited by 307
Minireview: Human Ovarian Cancer: Biology, Current Management, and Paths to Personalizing Therapy
Romero, I., & Bast, R. C. (2012) · Endocrinology · doi:10.1210/en.2011-2123 · Cited by 286
Self-citationTan, T. Z., Miow, Q. H., Huang, R. Y., Wong, M. K., Ye, J., Lau, J. A., Wu, M. C., Bin Abdul Hadi, L. H., Soong, R., Choolani, M., et al. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201201823 · Cited by 281
Modeling High-Grade Serous Ovarian Carcinogenesis from the Fallopian Tube
Karst, A. M., Levanon, K., & Drapkin, R. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1017300108 · Cited by 280
Cell Origins of High-Grade Serous Ovarian Cancer
Kim, J., Park, E., Kim, O., Schilder, J., Coffey, D., Cho, C.-H., & Bast, R. (2018) · Cancers · doi:10.3390/cancers10110433 · Cited by 264
Self-citationHippo Pathway Effector Yap Is an Ovarian Cancer Oncogene
Hall, C. A., Wang, R., Miao, J., Oliva, E., Shen, X., Wheeler, T., Hilsenbeck, S. G., Orsulic, S., & Goode, S. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1242 · Cited by 263
Wang, S., Zhao, X., Khimji, I., Akbas, R., Qiu, W., Edwards, D., Cramer, D. W., Ye, B., & Demirci, U. (2011) · Lab on a Chip · doi:10.1039/c1lc20479c · Cited by 254
Rizvi, I., Gurkan, U. A., Tasoglu, S., Alagic, N., Celli, J. P., Mensah, L. B., Mai, Z., Demirci, U., & Hasan, T. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1216989110 · Cited by 234
Motohara, T., Masuda, K., Morotti, M., Zheng, Y., El-Sahhar, S., Chong, K. Y., Wietek, N., Alsaadi, A., Carrami, E. M., Hu, Z., et al. (2019) · Oncogene · doi:10.1038/s41388-018-0637-x · Cited by 218
Rosanò, L., Cianfrocca, R., Spinella, F., Di Castro, V., Nicotra, M. R., Lucidi, A., Ferrandina, G., Natali, P. G., & Bagnato, A. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2325 · Cited by 187
Marchini, S., Fruscio, R., Clivio, L., Beltrame, L., Porcu, L., Nerini, I. F., Cavalieri, D., Chiorino, G., Cattoretti, G., Mangioni, C., et al. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2012.06.026 · Cited by 176
Stemness and chemoresistance in epithelial ovarian carcinoma cells under shear stress
Ip, C. K. M., Li, S.-S., Tang, M. Y. H., Sy, S. K. H., Ren, Y., Shum, H. C., & Wong, A. S. T. (2016) · Scientific Reports · doi:10.1038/srep26788 · Cited by 128
Upregulation of miR-21 in Cisplatin Resistant Ovarian Cancer via JNK-1/c-Jun Pathway
Echevarría-Vargas, I. M., Valiyeva, F., & Vivas-Mejía, P. E. (2014) · PLoS ONE · doi:10.1371/journal.pone.0097094 · Cited by 118
Biodegradable hybrid polymer micelles for combination drug therapy in ovarian cancer
Desale, S. S., Cohen, S. M., Zhao, Y., Kabanov, A. V., & Bronich, T. K. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.04.026 · Cited by 110
Zhang, C., Zhang, Z., Zhang, S., Wang, W., & Hu, P. (2017) · Medical Science Monitor · doi:10.12659/msm.901667 · Cited by 70
Assessing the in Vivo Efficacy of Doxorubicin Loaded Hyaluronan Nanoparticles
El-Dakdouki, M. H., Xia, J., Zhu, D. C., Kavunja, H., Grieshaber, J., O’Reilly, S., McCormick, J. J., & Huang, X. (2014) · ACS Applied Materials & Interfaces · doi:10.1021/am404946v · Cited by 69
The TGFβ pathway stimulates ovarian cancer cell proliferation by increasing IGF1R levels
Alsina‐Sanchis, E., Figueras, A., Lahiguera, Á., Vidal, A., Casanovas, O., Graupera, M., Villanueva, A., & Viñals, F. (2016) · International Journal of Cancer · doi:10.1002/ijc.30233 · Cited by 57
“This low survival rate is mainly because of intrinsic and acquired resistance to platinum-based chemotherapy.(1,3)”
BackgroundXu, S., Yang, Y., Dong, L., Qiu, W., Yang, L., Wang, X., & Liu, L. (2014) · Scientific Reports · doi:10.1038/srep05646 · Cited by 50
Fu, Y., Li, J., Cai, W., Huang, Y., Liu, X., Ma, Z., Tang, Z., Bian, X., Zheng, J., Jiang, J., et al. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.11.018 · Cited by 48
SALL4 is a marker of poor prognosis in serous ovarian carcinoma promoting invasion and metastasis
YANG, M., XIE, X., & DING, Y. (2016) · Oncology Reports · doi:10.3892/or.2016.4545 · Cited by 30
Integrated genomic analyses of ovarian carcinoma
The Cancer Genome Atlas Research Network (2011) · Nature · doi:10.1038/nature10166 · Cited by 129
Metadata
- Authors
- Bast, R. C., Hennessy, B., & Mills, G. B.
- Venue
- Nature Reviews Cancer
- Published
- 2009-06
- Volume
- 9
- Issue
- 6
- Pages
- 415-428
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2090968329
- Cited by
- 1,358
- References
- 117
- FWCI
- 10.56
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.